OKYO Pharma Ltd (OKYO) is a biopharmaceutical company that specializes in the development of life-changing therapies for patients with serious diseases. The company's primary focus is on developing therapies that can treat inflammatory eye diseases and chronic pain - serious medical conditions for which there are currently limited therapeutic options.
OKYO's novel patented drug technology is born out of extensive research conducted by renowned scientist Dr. Rajesh Khanna at the University of Arizona. The technology revolves around developing proprietary, chemically-engineered molecules to mimic the body's natural inflammation regulatory processes, targeting the G protein-coupled receptor (GPCR) class, particularly involving Chemerin and GPR18 receptors.
In the ophthalmology space, OKYO is developing OK-113, an innovative potential treatment for dry eye disease, one of the most common eye conditions that affect millions of people worldwide. In the pain management area, they are working on OK-225, designed to control neuropathic pain, a kind of chronic pain associated with nerve damage due to illnesses such as diabetes, shingles, or cancer, therefore improving patients' quality of life.
OKYO Pharma Ltd. is a public company listed on the London Stock Exchange (LSE) under the ticker symbol OKYO. However, it de-listed from the LSE in 2020 and is currently uplisting to NASDAQ, the leading stock exchange for biotech companies. Of course, this move indicates OKYO's matured position and ambition to strive forward in the biotech world's fast-paced, competitive landscape.
The Company's management team is composed of highly experienced pharmaceutical and biotech industry veterans who have significant clinical development and commercialization expertise, necessary to facilitate OKYO Pharma's ambitious growth plans. The team's expertise, combined with the strategic collaboration with global academic and commercial partners, places the company in a strong position to advance its innovative drug candidates through clinical development and into the market.
For investors, OKYO Pharma represents a company positioned at the frontiers of medical research, with potential treatments that could revolutionize the management of certain chronic diseases. Despite facing the usual challenges and uncertainties associated with drug development, OKYO’s innovative technological approach, combined with their strategic positioning, makes them an intriguing proposition. For patients, OKYO's work offers hope of significant improvement in disease management, potentially transforming their daily lives.